DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Revenue of DICE Therapeutics, Inc. (DICE)
Revenue in 2022 (TTM): $
According to DICE Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of DICE Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $ | $ | $-83,008,000 | $-83,887,000 | $-81,664,000 |
| 2021 | $1.13 M | $1.13 M | $-47,467,000 | $-48,959,000 | $-48,472,000 |
| 2020 | $863 K | $863 K | $-22,885,000 | $-23,739,000 | $-23,752,000 |
| 2019 | $5.78 M | $5.78 M | $-12,206,000 | $-12,938,000 | $-12,964,000 |